Currently, a U.S. shortage of carboplatin and cisplatin exists that will likely last several months and possibly longer. Platinum drug shortages were first reported to the U.S. Food and Drug Administration (FDA) on February 10, 2023.
Below you’ll find valuable information including:
-
SGO, FWC, and GOG-F Communiques
-
Webinars
-
SGO Member Community Group
-
Media Coverage & Additional Resources
-
What You Can Do
SGO Statement: Carboplatin and Cisplatin ShortagesFWC Statement: Carboplatin and Cisplatin ShortagesSGO, FWC, and GOG-F Communique: Shortages and Treating Cervical, Vulvar, and Vaginal Cancers
SGO, FWC, and GOG-F Communique: Considerations When Treating Gestational Trophoblastic Neoplasia in the Setting of a Methotrexate Shortage
SGO, FWC, and GOG-F Communique: Considerations When Treating Patients with Gynecologic Cancers on Clinical Trials in the Setting of Chemotherapy Shortages
SGO, FWC, and GOG-F Communique: Considerations When Treating Persons with Ovarian, Fallopian Tube, and Peritoneal Cancers in the Setting of Cisplatin and Carboplatin Shortages
SGO, FWC, and GOG-F Communique: Considerations When Treating Persons with Endometrial Malignancies in the Setting of Cisplatin and Carboplatin Shortages
NEW: SGO, FWC, and GOG-F Communique: CONSIDERATIONS WHEN TREATING PERSONS WITH GYNECOLOGIC CANCERS IN THE SETTING OF PEGYLATED LIPOSOMAL DOXORUBICIN SHORTAGES